



Quarterly Investor Presentation

January 21, 2022

Authorised by the Board of Directors of Genetic Technologies Limited

ASX: GTG
NASDAQ: GENE





Notice: Forward looking statements

The purpose of the presentation is to provide an update of the business of Genetic Technologies Limited (the Company) ACN: 009 212 328 (ASX:GTG; NASDAQ:GENE). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by the Company and should not be relied upon as an independent source of information. Please refer to the Company's website and/or the Company's filings to the ASX and SEC for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by the Company. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Our Overview

01

Our Vision &
Brand Pillars

2021 Overview
Where are
we now

02

Our Markets

Expanded to over
40 countries

03

Our Acquisition

EasyDNA –
Execution a multi
brand strategy

04

Our Channels &
Divisions

Pathways, Divisions
and Category
Segmentation

05

Our Portfolio &
Innovation

Executing through
cutting edge
innovation and 'game
changing' partnerships

06

Our Capabilities

Aligning our internal
capability aligned to
execution

01: Unlocking personalised preventative health

Significant progress has been made in understanding the role of hereditary risk in chronic disease, however, many chronic conditions cannot be predicted by this risk alone.

We're transforming the conversation. Transitioning from a one-size-fits-all model to personalised, predictive health assessment – where each person has the information, they need to manage their health according to their own risk.

Backed by over 20 years of experience, our doctors, scientist and technicians are translating genetic information into multi-tests that uniquely combine genetic and clinical risk models to predict risk of chronic diseases before onset.

We're empowering physicians to improve health outcomes for people around the world. Tracking disease to its source. Enabling a new era of personalised medicine.



01: geneType's pillars reflect its commitment to personalised, preventative health



Unequaled experience

Scientific team leveraging their extensive research track record in breast and colorectal to expand our medical-grade genetic test portfolio into further cancers and chronic conditions



Leading integrated technology

The sophisticated integration of genomic and clinical risk factors deliver the most complete risk assessments for serious diseases in the world – the foundation of geneType



Relentless innovation

Accelerating the world's transition to personalised, preventative health care by converting genetic data into actionable solutions for consumers and doctors




Setting new standards

Setting clinical, safety and ethical standards to ensure the best health outcomes

genetype's Polygenic Risk Scores (PRS) platform is a proprietary risk stratification platform developed over the past decade integrating clinical and genetic risk delivering actionable outcomes from physicians and individuals

01: Results & Highlights Qtr. 2, 2021

Cash Receipts (A\$'000)




- Cash receipts in 2QFY22 are +113% versus the prior quarter (1QFY22) to A\$1.8 million following the successful integration of EasyDNA in the quarter
- Multi-Test technical validation complete and submitted to NATA¹ and CMS² for final regulatory approval ahead of the commercial release
- US patent application for novel geneType COVID-19 Risk Test has been accepted and cross validation study completed in independent cohort confirming test performance and utility
- Enhanced patient distribution network with expanded partnership agreement with 1Health and IBX
- Study of 200,000 participants presented at 2021 San Antonio Breast Cancer Symposium validating the risk model with an expanded panel of 313 Single Nucleotide Polymorphisms (SNPs)
- Strong cash balance of A\$13.5 million, providing 22 months³ of runway post the integration and revenue contribution from EasyDNA

¹ National Association of Testing Authorities, Australia

² Centers for Medicare & Medicaid Services

³ Based on projected cash flows

01: Our 2021 Snapshot



¹ GeneType for Breast Cancer and Colorectal Cancer certified for sale via online sales platform.

² Runway based on current cash projections and including the acquisition of EasyDNA

³ Subject to local regulatory requirement

02: Our Markets and Collaborators

Genetype and EasyDNA Brands now available in more than 40 countries

United States

geneType® Polygenic Risk Score (PRS) tests for breast, colorectal cancer and COVID-19 Risk Test available through CLIA Certified "High Complexity" Laboratories.

Further products expected to be submitted in next 12 months

Europe & UK

Commencing CE certification enabling EU launch of Novel genetic risk test in CY2022

EasyDNA available multiple EU countries and UK

Asia (Inc. SEA, China and India)

Commencing a scoping and Prioritising a market entry strategy into Asia

EasyDNA available in multiple countries across SEA

Australia & New Zealand

Certification by Australian regulators **NATA**, to sell into the Australian market

Two products¹ currently certified and further products expected to be submitted in next 12 months



¹ GeneType for Breast Cancer and Colorectal Cancer certified for sale via online sales platform.

02: A strategy to own the personalised, preventative health testing market

Brand Recognition and Advocacy

Thought leadership



Demonstrating our leadership by informing the conversation on personalised, preventative health care

Seeded content



Amplifying our impact by starting and informing conversations in key consumer and clinical channels

GeneType advocacy



Building a group of clinicians and consumers willing to share with their colleagues and friends their experience with geneType

Commercialization and Branding

Sales & marketing



Core set of sales and marketing tactics and assets tailored by therapeutic area, and adapted by geography

Medical education




Motivating trial and purchase with medical education for clinicians and consumers

GeneType Hubs




Empowering clinicians to use geneType. Their clinic becomes a geneType Hub that taps into a GP referral network and reinforcing their leadership in personalised, preventative health

02: A cutting-edge geneType brand relaunched





02: Core set of sales material to empower clinicians and consumers



03: EasyDNA – Establishing our Lifestyle Division


- Acquired EasyDNA in August 2021 for US\$4 million
- Current revenues of US\$4.63 million through retail sales of its at-home DNA tests
- Agreements with 12 laboratories in North America, AsiaPac and Europe
- Showing good baseline growth
- A platform to launch the geneType Multi Test and portfolio of serious disease tests across 40 countries*
- EasyDNA currently sells paternity, oncology and health and wellbeing genomics-based tests
- This acquisition provides Genetic Technologies the foundation to grow in **40 countries**
- 2022 will see us expand our portfolio of tests with availability in more channels and more markets



04: Our Pathways

Direct to consumer testing (DTC) with no medical supervision

Recent Acquisition announced for EasyDNA



Leverage for paternity, ancestry, gut microbiome testing and non-medical related genomic tests

www.easydna.com



Provides Genetic Technologies the foundation to grow in 40 countries

Agreements with 12 laboratories in North America, AsiaPac and Europe



Consumer initiated testing (CIT) with medical supervision

Launched US and Australia CIT platforms in 2020 with medical supervision with:

InTeleLabs in the US

Phenix Health in Australia



Current products include:

geneType for Breast Cancer

geneType for Colorectal Cancer

AUD\$349 / US\$249 per test



Medical – Business to Business (B2B)

A execution plan curated for

Payers / Insurers*

Primary Care Physicians

Specialists

Surgeons

Allied Health



Health Economic modeling being completed by ALVA10*

Certifying reimbursable testing platform


BRCA test

LYNCH Syndrome test



04: Our Divisions

- Emerging divisions
- Existing divisions



NEW – Universal collection test kit to support Multi Test Launch





NEW Universal sample collection kit with TGA, FDA and EU regulatory approval¹



BC = Breast Cancer; CRC = Colorectal Cancer; PC = Prostate Cancer; CVD = Cardiovascular Disease; IHD = Ischemic Heart Disease; Atrial Fibrillation
1. TGA, FDA and EU regulatory approval granted to the sponsor, DNA Genotek


04: Segmentation framework

Brand, channel and testing categories



*Available upon regulatory approval
 All test categories live and active, some categories/ tests will transfer from EasyDNA → GeneType

05: Our Portfolio – Driving Growth



1. Subject to regulatory approval

NEW: Covid Risk Test (US)

<https://genetype.com/for-individuals/covid-19>

Find out about your risk of developing severe COVID-19. And take action today.

It's not just age that increases the risk of developing severe symptoms of infected with SARS-Cov-2.¹

You're probably also heard of other risk factors, or "comorbidities." Hypertension, diabetes, and respiratory disease are among some common comorbidities.²

DNA
Small changes in our DNA have a strong link to COVID-19 severity.

Clinical history
Medical risk factors can impact COVID-19 severity.

GeneType for COVID-19 severity provides simple, actionable results.

Personalised risk score. Personalised health plan.

GeneType for COVID-19 Severity allows us to identify adults in our community at greater risk of developing severe symptoms requiring hospitalization.

GeneType testing is simple

- Step 1**
Purchase your geneType test kit via this website or through your healthcare professional.
- Step 2**
Complete a simple questionnaire, spit in the tube provided and return both to genetype.
- Step 3**
When your results are ready, you will be notified by our clinical partners, Elicity or Thera Health. If you prefer, you can also be notified to make a follow-up appointment with your healthcare professional if you prefer through them.



The link goes directly to Vitagene landing page:

<https://vitagene.com/products/covid-19-risk-test/>

Saliva Collection Kit

IBX COVID-19 Risk Test

- At Home Self-Administer Saliva
- Results in 3-5 days
- Includes return shipping label

\$175 Free Shipping

QTY: 1

Identify greater risk of developing severe symptoms requiring hospitalization.

How the COVID-19 Risk Test is Helpful

The COVID-19 Risk Test provided by IBX Labs allows us to identify adults in our communities at greater risk of developing severe symptoms requiring hospitalization. This test can protect our population by identifying the most vulnerable. By understanding who among us are at greater risk for developing severe disease, we can be more thoughtful about safety protocols, and personal risks that we are willing to take for ourselves and our loved ones.

- FDA Approval**
This test is not FDA approved but has been tested and approved by a CLIA-certified laboratory.
- Insurance**
Currently, this test is not covered by insurance.

Certified Labs
Our clinical labs meet the standards set by The Clinical Laboratory Improvement Amendments of 1988 (CLIA) and College of American Pathologists (CAP), ensuring the

Physician Reviewed
Vitagene tests are reviewed and approved by an independent board-certified physician within your state. This ensures that any test ordered is relevant to your health and

HIPAA Data Security
Vitagene is HIPAA compliant and takes your privacy very seriously. We use state-of-the-art, bank-grade encryption to ensure your data is stored securely, and under no

05: Our Innovation - Multi Test

A companion diagnostic PRS to help identify risk of serious disease for up to 70% of Mortalities and Morbidities
Committed to continually invest in developing multi population testing solutions

● Phase 1 Launch ²

● Phase 2 Launch ³

Oncology

- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Melanoma
- Pancreatic Cancer
- Ovarian Cancer

1

Cardiovascular

- Atrial Fibrillation
- Coronary Artery Disease

2

Metabolic

- Type 2 Diabetes

3

Mental Health

- Talioz

4

GeneType Multi-test to include >70% of mortality & morbidity



NEW Universal sample collection kit with TGA, FDA and EU regulatory approval¹

1. TGA, FDA and EU regulatory approval granted to the sponsor, DNA Genotek
 2. Commercial availability expected Q1 CY2022
 3. Commercial availability expected Q2 CY2022

05: Our Innovation - Multi Test

Phase 1 Launch Test reports - NATA Validation pack submitted

The image displays six GeneType test reports, each for a different cancer or condition. Each report includes patient details, a risk assessment, and a comparison to average risk.


- Ovarian Cancer Risk Assessment Test Report:** Patient is at an **INCREASED** risk of ovarian cancer. 5 Year Risk: 0.07%, Lifetime Risk: 2.30%.
- Breast Cancer Risk Assessment Test Report:** Patient is at an **INCREASED** risk of breast cancer. 5 Year Risk: 1.31%, Lifetime Risk: 25.04%.
- Prostate Cancer Risk Assessment Test Report:** Patient's risk of developing prostate cancer is: 5 Year Risk: 0.23%, Lifetime Risk: 50.00%.
- Coronary Artery Disease Risk Assessment Test Report:** Patient is at a **HIGH** risk of coronary artery disease. 10 Year Risk: 47.03%.
- Colorectal Cancer Risk Assessment Test Report:** Patient is at a **MODERATE** lifetime risk of developing colorectal cancer. 10 Year Risk: 3.14%, Lifetime Risk: 23.69%.
- Type 2 Diabetes Risk Assessment Test Report:** Patient is at an **INCREASED** risk of Type 2 Diabetes. 8 Year Risk: 32.03%.

Each report also features a bar chart comparing the patient's risk to the average risk for similar age and ethnicity. The reports include sections for interpretation and a patient risk profile (Low, Intermediate, High).

05: Our Innovation – Integrated Polygenic risk


geneType integrates genetic risk and clinical risk to better stratify individual risk. Patients with potentially high risk may exceed actionable clinical guidelines 10 – 15 years earlier than those with low risk ^{1,2,3}

Breast Cancer (BC)¹




↑ Low polygenic risk score
 ↑ High polygenic risk score

Colorectal Cancer (CRC)²



Chronic Heart Disease (CHD)³



geneType detects patients at an actionable risk of serious disease
 10 – 15 years earlier than currently possible
 Potentially significantly improving patient outcomes and health economics

¹ Mavaddat et al. (2015) JNCI.
² Jenkins et al. (2019) Familial Cancer.
³ Abraham et al. (2016) Eur Heart J.

05: Significant market opportunity

To provide predictive, pre-symptomatic testing to inform lifestyle choices and healthcare discussions
 Guideline driven, reimbursable for inherited and non inherited disease

Near Term Addressable Market

281,550⁵
 Diagnosis of breast cancer annually in United States
(19,974 cases diagnosed annually in Australia³)

+

1st degree relatives

=

GTG Target Market for

BRCA Panel + Breast Cancer PRS Testing
 providing up to 100% genetic risk cover screening



149,500⁶
 Diagnosis of colorectal cancer annually in United States
(15,494 cases diagnosed annually in Australia⁴)

+

1st degree relatives

=

GTG Target Market for


LYNCH Syndrome Panel + Colorectal Cancer PRS Testing
 providing up to 100% genetic risk cover screening



Global Predictive Genetic Testing Market anticipated to exceed \$28bn by 2026¹

1. Genetic Testing Market Size By Test Type (Predictive Testing, Carrier Testing, Prenatal and New-born Testing, Diagnostic Testing, Pharmacogenomic Testing, Nutrigenomic Testing), By Application (Cancer, Genetic Disease, Cardiovascular Disease), Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2020 – 2026; Published Date: Feb 2020; Authors: Sumant Ugalmugle, Rupali Swain
 2. PRS = Polygenic Risk Score
 3. <https://www.canceraustralia.gov.au/affected-cancer/cancer-types/breast-cancer/breast-cancer-australia-statistics>
 4. <https://www.canceraustralia.gov.au/affected-cancer/cancer-types/bowel-cancer/bowel-cancer-colorectal-cancer-australia-statistics>
 5. <https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html>
 6. <https://www.cancer.net/cancer-types/colorectal-cancer/statistics>

06: Our Capability



01

Our Vision &
Brand Pillars

02

Our Markets

Targeted and
deliberate

03

Our
Acquisition

Positioned for
growth

04

Our Channels &
Divisions

Focused and
distinct

05

Our Portfolio &
Innovation

Cutting edge
innovation

06

Our Capabilities

Aligned to
execute



Thank you

Investor Relations and Media (US)
Dave Gentry
Red Chip
Cell: +1 407 491 4498
1 800 RED CHIP (733 2447)
dave@redchip.com

Investor Relations - AUS
Stephanie Ottens
Market Eye
+61 434 405 400
stephanie.ottens@marketeye.com.au



Appendices

Our Intellectual Property

7 Patents granted in the US

- Patent 11,031,098, Computer systems and methods for genomic analysis
- Patent 10,683,549, Methods for assessing risk of developing breast cancer
- Patent Nos. 9,051,617; 9,068,229 and 9,702,011 covering three of the core genetic markers included in the BREVAGenplus® risk assessment test
- Patent No. 7,127,355 offering broad protection re: methods of genetic analysis (the concept of combining clinical risk assessment with genetic risk factors to improve predictability over clinical risk assessment alone)
- Patent No. 6,969,589 covering the identification of informative SNPs

5 Patents granted in China

- Patent Nos. 200680051710.0; 201310524782.4; 201310524916.2 and 201310524765.0 “Markers for Breast Cancer”
- Patent No. 201080033130.5 Methods for Breast Cancer Risk Assessment

5 Patents granted in Hong Kong

- Patent Nos. 09101235.4; 12112875.1; 12112368.5 and 12112874.2 “Markers for Breast Cancer”
- Patent No. 12109000.5 Methods for Breast Cancer Risk Assessment

9 Patent families pending

- Methods for breast cancer risk assessment
- Methods for assessing risk of developing breast cancer
- Improved methods for assessing risk of developing breast cancer
- Markers for breast cancer
- Methods for genetic analysis
- Methods for genomic analysis
- Methods for assessing risk of developing colorectal cancer
- Methods of assessing risk developing a disease
- Methods for assessing risk of developing a severe response to coronavirus infection

Board and Management: Sales and Scientific expertise leading GTG



Mr. Peter Rubinstein
BEd, LLB
Chairman - Non -
Executive Director



Dr. Lindsay Wakefield
MBBS
Non - Executive
Director



Mr Nick Burrows
B.Com, FAICD, FCA,
FGIA, FTIA, F Fin
Non - Executive
Director



Simon Morriss
GAICD
Chief Executive Officer



**Dr. Jerzy "George"
Muchnicki**
MBBS
Executive Director &
Chief Medical Officer



Erika Spaeth
PhD
Director of Clinical
Affairs & Medical
Education



Richard Allman
BSc, PhD
Chief Scientific
Officer



Mike Tonroe
BSc, FCA, MAICD
Chief Financial
Officer



Carl Stubbings
Chief Commercial
Officer

Strong Scientific Leadership: Advisory Board



Professor Jon Emery

MBBCh MA DPhil FRACGP MRCGP
Research & Education Lead, Primary
Care Integration, Victorian
Comprehensive Cancer Centre Herman
Chair of Primary Care Cancer
Research, University of Melbourne



Professor Finlay Macrae AO

MBBS, MD, FRACP, FRCP, AGAF MWGO
is Principal Fellow and Professor,
Department of Medicine, University of
Melbourne, and Head of Colorectal
Medicine and Genetics, The Royal
Melbourne Hospital



Ora K. Gordon, M.D.

MD, MS, FACMG
Regional Medical Director, Center for
Clinical Genetics & Genomics. Clinical
Director, PSJH Population Health
Genomics Program. Chair, Integrated
Network Cancer Program, Professor of
Genetics, St John Cancer Institute

Financial Overview


- Cash burn of A\$2.2 million in Q2 FY'22 (compared to Q1 FY'22: A\$1.9 million) as we continue to grow EasyDNA brand sales and develop and commercialize our geneType tests
- Cash reserves of A\$13.5 million after EasyDNA acquisition costs of A\$3.5 million give 22 month¹ runway to:
 - Support the introduction and distribution of new geneType products in the United States and Europe
 - Develop the direct-to-consumer sales channel through EasyDNA
 - Reimbursement studies for the polygenic risk tests;
 - Introduction of germline testing division;
 - General product research and development; and
 - For general working capital and potential acquisitions.

A\$'000	30 Sep 2021	31 Dec 2021	Change
Net operating cashflow	(1,939)	(2,157)	(11%)
Receipts from customers	850	1,809	113%
Research and Development and Staff costs	1,321	1,313	1%
Cash	15,742	13,509	(14%)

¹ Based on cashflow projections

Corporate Overview

Top 50 share registry breakdown



Dual Listed on the ASX and Nasdaq

Financial Information

Share price (AUD) as at 20 January 2022	0.5c
ADR price (USD) as at 20 January 2022	\$2.08
Ord Shares on Issue (M)	9,234
ASX 52-week trading (AUD low/high)	0.4/1.4c
Nasdaq 52-week trading (USD low/high)	1.77/8.18
Market Cap (A\$/US\$M)	46.13/33.48
Cash at 31 December 2021	A\$13.5m
Cash at 30 September 2021	A\$15.7m
Debt (30 September and 31 December 2021)	nil

Defined Terms

Common Complex Diseases (CCP) – A complex disease is caused by the interaction of multiple genes and environmental factors. Complex diseases are also called multifactorial. Examples of common complex diseases include cancer and heart disease.

Polygenic risk score - a number associated with one's disease risk based on the aggregated effects of individual risk variants through a multiplicative algorithm.

Variant - Single Nucleotide polymorphism (SNP), an alteration in DNA that may be a common or rare event.

Genomic - pertaining to function of genetics from structure to relationship between genetic events.

Genetic - pertaining to a gene.

GWAS - genome-wide association studies are large population level studies which enable scientists to identify genes and genetic markers involved in human disease. This method searches the genome for SNPs that occur more frequently in people with a particular disease than in people without the disease. Each study can look at hundreds or many thousands of SNPs at the same time. Researchers use data from this type of study to pinpoint genetic variations that may contribute to a person's risk of developing a certain disease.

SNP - Single nucleotide polymorphisms, frequently called SNPs (pronounced "snips"), are the most common type of genetic variation among people. Each SNP represents a difference in a single DNA building block, called a nucleotide. For example, a SNP may replace the nucleotide cytosine (C) with the nucleotide thymine (T) in a certain stretch of DNA.

Serious Disease Risk (SDR) - Risk associated with acquiring COVID-19 and requiring hospitalisation with its associated morbidities and mortalities.

Germline Testing – Germline testing is done on cells that do not have cancer. It is done to see if a person has a gene mutation that is known to increase the risk of developing cancers and other health problems. This test uses cells (such as blood or skin cells) that do not have any cancer cells. Germline mutations can sometimes be passed down from parents.

Clinical Laboratory Improvement Amendments (CLIA) - Regulates laboratory testing and require clinical laboratories to be certified by the Center for Medicare and Medicaid Services (CMS) before they can accept human samples for diagnostic testing

National Association of Testing Authorities (NATA) - the authority responsible for the accreditation of laboratories, inspection bodies, calibration services, producers of certified reference materials and proficiency testing scheme providers throughout Australia. It is also Australia's compliance monitoring authority for the OECD Principles of GLP. NATA provides independent assurance of technical competence through a proven network of best practice industry experts for customers who require confidence in the delivery of their products and services.

Next Generation Sequencing (NGS) – Next-generation sequencing (NGS), also known as high-throughput sequencing, is the catch-all term used to describe a number of different modern sequencing technologies. These technologies allow for sequencing of DNA and RNA much more quickly and cheaply than the previously used Sanger sequencing, and as such revolutionised the study of genomics and molecular biology.

Laboratory Developed Tests (LDT) – A type of in vitro diagnostic test that is designed, manufactured and used within a single laboratory.

Consumer Initiated Tests (CIT) - laboratory testing that is initiated by the consumer without a physician order but reviewed and communicated back to the consumer via a physician.

Direct to Consumer (DTC) – laboratory testing that is initiated by the consumer without a physician order. The results are reported back directly to the consumer.